|Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line|
DA Tweddle, AJ Malcolm, N Bown, ADJ Pearson, J Lunec
Cancer research 61 (1), 8-13, 2001
|The p53 pathway and its inactivation in neuroblastoma|
DA Tweddle, ADJ Pearson, M Haber, MD Norris, C Xue, C Flemming, ...
Cancer letters 197 (1-2), 93-98, 2003
|High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma|
J Carr-Wilkinson, K O'Toole, KM Wood, CC Challen, AG Baker, JR Board, ...
Clinical cancer research 16 (4), 1108-1118, 2010
|Increased frequency of aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines established at relapse|
J Carr, E Bell, ADJ Pearson, UR Kees, H Beris, J Lunec, DA Tweddle
Cancer research 66 (4), 2138-2145, 2006
|p53 is a direct transcriptional target of MYCN in neuroblastoma|
L Chen, N Iraci, S Gherardi, LD Gamble, KM Wood, G Perini, J Lunec, ...
Cancer research 70 (4), 1377-1388, 2010
|p53 cellular localization and function in neuroblastoma: evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells|
DA Tweddle, AJ Malcolm, M Cole, ADJ Pearson, J Lunec
The American journal of pathology 158 (6), 2067-2077, 2001
|MYCN oncoprotein targets and their therapeutic potential|
E Bell, L Chen, T Liu, GM Marshall, J Lunec, DA Tweddle
Cancer letters 293 (2), 144-157, 2010
|Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data|
M Łastowska, V Viprey, M Santibanez-Koref, I Wappler, H Peters, ...
Oncogene 26 (53), 7432-7444, 2007
JPH Fisher, DA Tweddle
Seminars in Fetal and Neonatal Medicine 17 (4), 207-215, 2012
|Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a …|
G Schleiermacher, J Michon, A Ribeiro, G Pierron, V Mosseri, H Rubie, ...
British journal of cancer 105 (12), 1940-1948, 2011
|Inhibition of poly (ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma|
RA Daniel, AL Rozanska, HD Thomas, EA Mulligan, Y Drew, ...
Clinical Cancer Research 15 (4), 1241-1249, 2009
|MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63|
LD Gamble, UR Kees, DA Tweddle, J Lunec
Oncogene 31 (6), 752-763, 2012
|Cell cycle regulation targets of MYCN identified by gene expression microarrays|
E Bell, J Lunec, D Tweddle
Cell cycle 6 (10), 1249-1256, 2007
|MYCN amplification remains prognostically strong 20 years after its “clinical debut”|
SL Cohn, DA Tweddle
European journal of cancer 40 (18), 2639-2642, 2004
|Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[131I] iodobenzylguanidine by neuroblastoma tumors|
S Carlin, RJ Mairs, AG McCluskey, DA Tweddle, A Sprigg, C Estlin, ...
Clinical cancer research 9 (9), 3338-3344, 2003
|The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage|
E Bell, R Premkumar, J Carr, X Lu, PE Lovat, UR Kees, J Lunec, ...
Cell Cycle 5 (22), 2639-2647, 2006
|A multilocus technique for risk evaluation of patients with neuroblastoma|
IM Ambros, B Brunner, G Aigner, C Bedwell, K Beiske, J Bénard, N Bown, ...
Clinical Cancer Research 17 (4), 792-804, 2011
|Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly (ADP-ribose) polymerase inhibitor AG-014699|
RA Daniel, AL Rozanska, EA Mulligan, Y Drew, HD Thomas, ...
British journal of cancer 103 (10), 1588-1596, 2010
|p53, SKP2, and DKK3 as MYCN target genes and their potential therapeutic significance|
L Chen, DA Tweddle
Frontiers in oncology 2, 173, 2012
|High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays|
J Carr, NP Bown, MC Case, AG Hall, J Lunec, DA Tweddle
Cancer genetics and cytogenetics 172 (2), 127-138, 2007